These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1030 related articles for article (PubMed ID: 28017471)

  • 21. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy.
    See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C
    Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy.
    Baughan TD; Dickson A; Osman EY; Lorson CL
    Hum Mol Genet; 2009 May; 18(9):1600-11. PubMed ID: 19228773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy.
    Groen EJN; Perenthaler E; Courtney NL; Jordan CY; Shorrock HK; van der Hoorn D; Huang YT; Murray LM; Viero G; Gillingwater TH
    Hum Mol Genet; 2018 Aug; 27(16):2851-2862. PubMed ID: 29790918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns.
    Doktor TK; Hua Y; Andersen HS; Brøner S; Liu YH; Wieckowska A; Dembic M; Bruun GH; Krainer AR; Andresen BS
    Nucleic Acids Res; 2017 Jan; 45(1):395-416. PubMed ID: 27557711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligonucleotides and spinal muscular atrophy: skipping along.
    Burghes AH; McGovern VL
    Genes Dev; 2010 Aug; 24(15):1574-9. PubMed ID: 20679391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of SMN to Emx-1 expressing cortical neurons is not sufficient to provide benefit to a severe mouse model of Spinal Muscular Atrophy.
    Taylor AS; Glascock JJ; Rose FF; Lutz C; Lorson CL
    Transgenic Res; 2013 Oct; 22(5):1029-36. PubMed ID: 23512182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splicing of the Survival Motor Neuron genes and implications for treatment of SMA.
    Bebee TW; Gladman JT; Chandler DS
    Front Biosci (Landmark Ed); 2010 Jun; 15(3):1191-1204. PubMed ID: 20515750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy.
    Ando S; Osanai D; Takahashi K; Nakamura S; Shimazawa M; Hara H
    J Pharmacol Sci; 2020 Dec; 144(4):204-211. PubMed ID: 33070839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes.
    Singh RN; Singh NN
    Adv Neurobiol; 2018; 20():31-61. PubMed ID: 29916015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy.
    Ramirez A; Crisafulli SG; Rizzuti M; Bresolin N; Comi GP; Corti S; Nizzardo M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
    Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain.
    Sumner CJ; Crawford TO
    J Clin Invest; 2018 Aug; 128(8):3219-3227. PubMed ID: 29985170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells.
    Lin X; Li JJ; Qian WJ; Zhang QJ; Wang ZF; Lu YQ; Dong EL; He J; Wang N; Ma LX; Chen WJ
    Oncotarget; 2017 Jun; 8(26):42030-42042. PubMed ID: 28159932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage.
    Jangi M; Fleet C; Cullen P; Gupta SV; Mekhoubad S; Chiao E; Allaire N; Bennett CF; Rigo F; Krainer AR; Hurt JA; Carulli JP; Staropoli JF
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):E2347-E2356. PubMed ID: 28270613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice.
    Workman E; Saieva L; Carrel TL; Crawford TO; Liu D; Lutz C; Beattie CE; Pellizzoni L; Burghes AH
    Hum Mol Genet; 2009 Jun; 18(12):2215-29. PubMed ID: 19329542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypothermia improves disease manifestations in SMA mice via SMN augmentation.
    Tsai LK; Chen CL; Tsai YC; Ting CH; Chien YH; Lee NC; Hwu WL
    Hum Mol Genet; 2016 Feb; 25(4):631-41. PubMed ID: 26647309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Biochemistry of Survival Motor Neuron Protein Is Paving the Way to Novel Therapies for Spinal Muscle Atrophy.
    Lomonte P; Baklouti F; Binda O
    Biochemistry; 2020 Apr; 59(14):1391-1397. PubMed ID: 32227847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.